The deals cover the company's synthetic DNA and next-generation sequencing products, including its newly launched target enrichment line.
The grant money will be provided through the EC's Horizon 2020 European Innovation Council program and Bpifrance's innovation development programs.
The company, which recently entered the next-generation sequencing sample prep market, said it has raised $259 million since it was founded in 2013.
Twist Bioscience wants to shrink DNA synthesis to smaller and smaller volumes, possibly enabling DNA storage, according to the San Francisco Chronicle.
The company, which was founded in 2016, said it would use the funding to further develop its core gene synthesis platform.
DNA Script has acquired an exclusive license to a novel DNA building block for use in enzymatic DNA synthesis.
Maravai was launched in 2014 by private equity firm GTCR in partnership with two former Gen-Probe executives.
The Boston-based synthetic biology company will use the proceeds to grow Bioworks3, its new organism foundry, and to expand into new markets.
Oxford will license its SnapFast platform to Twist, to provide it with a range of application-specific expression vectors it can use to clone synthesized DNA.
Both deals should advance Ginkgo's custom microbe business as it expands into consumer goods markets such as cosmetics, nutrition, and food.
A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.
Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.
A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.
In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more